The advent of the CRISPR/Cas technology, which simplifies gene editing and increases efficiency compared to RNA interference, has opened up unprecedented possibilities in cancer research, particularly in investigating the molecular mechanisms underlying the KRAS-driven tumor initiation, progression, and response to anti-cancer therapies. The gene discussed is KRAS; the disease is cancer.